Inhibiting IL-6 in COVID-19: we are not sure.
作者信息
Honore Patrick M, Barreto Gutierrez Leonel, Kugener Luc, Redant Sebastien, Attou Rachid, Gallerani Andrea, De Bels David
机构信息
ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium.
Centre Hospitalier Universitaire Brugmann, Brussels, Belgium.
出版信息
Crit Care. 2020 Jul 27;24(1):463. doi: 10.1186/s13054-020-03177-x.
Abstract
摘要
相似文献
1
Inhibiting IL-6 in COVID-19: we are not sure.在新冠肺炎中抑制白细胞介素-6：我们并不确定。
Crit Care. 2020 Jul 27;24(1):463. doi: 10.1186/s13054-020-03177-x.
2
Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19.体外细胞因子吸附作为COVID-19中白细胞介素-6药物抑制的替代方法。
Crit Care. 2020 Aug 20;24(1):514. doi: 10.1186/s13054-020-03238-1.
3
COVID-19: Respiratory support outside the intensive care unit.新型冠状病毒肺炎：重症监护室外的呼吸支持
Lancet Respir Med. 2020 Jun;8(6):538-539. doi: 10.1016/S2213-2600(20)30176-4. Epub 2020 Apr 9.
4
Heterogeneity of Acute Respiratory Distress Syndrome in COVID-19: "Typical" or Not?新型冠状病毒肺炎中急性呼吸窘迫综合征的异质性：是否为“典型”？
Am J Respir Crit Care Med. 2020 Aug 15;202(4):618-619. doi: 10.1164/rccm.202004-1106LE.
5
COVID-19- versus non-COVID-19-related Acute Respiratory Distress Syndrome: Differences and Similarities.新型冠状病毒肺炎相关与非新型冠状病毒肺炎相关急性呼吸窘迫综合征：差异与相似之处
Am J Respir Crit Care Med. 2020 Nov 1;202(9):1301-1304. doi: 10.1164/rccm.202005-2025LE.
6
Covid-19, Angiogenesis, and ARDS Endotypes.新型冠状病毒肺炎、血管生成与急性呼吸窘迫综合征的内型
N Engl J Med. 2020 Jul 9;383(2):182-183. doi: 10.1056/NEJMe2018629. Epub 2020 May 21.
7
Coronavirus in China.中国的冠状病毒。
Lancet Respir Med. 2020 Mar;8(3):238. doi: 10.1016/S2213-2600(20)30056-4. Epub 2020 Feb 3.
8
Risk of COVID-19 disease in the elderly population and physiotherapy.老年人群中感染新型冠状病毒肺炎的风险与物理治疗
Physiotherapy. 2020 Sep;108:76-77. doi: 10.1016/j.physio.2020.05.003. Epub 2020 Jun 2.
9
Treatment of COVID-19 by Inhaled NO to Reduce Shunt?吸入一氧化氮治疗新型冠状病毒肺炎以减少分流？
Am J Respir Crit Care Med. 2020 Aug 15;202(4):618. doi: 10.1164/rccm.202004-0940LE.
10
Extracorporeal membrane oxygenation for acute respiratory distress syndrome in patients with coronavirus disease 2019: what do we know so far?2019冠状病毒病患者急性呼吸窘迫综合征的体外膜肺氧合：我们目前了解多少？
Perfusion. 2020 Sep;35(6):558-561. doi: 10.1177/0267659120934279. Epub 2020 Jun 24.
引用本文的文献
1
Explanatory predictive model for COVID-19 severity risk employing machine learning, shapley addition, and LIME.采用机器学习、Shapley 加法和 LIME 算法对 COVID-19 严重程度风险进行解释性预测模型。
Sci Rep. 2023 Apr 4;13(1):5481. doi: 10.1038/s41598-023-31542-7.
2
Perilla Fruit Water Extract Attenuates Inflammatory Responses and Alleviates Neutrophil Recruitment via MAPK/JNK-AP-1/c-Fos Signaling Pathway in ARDS Animal Model.紫苏子水提取物通过丝裂原活化蛋白激酶/应激活化蛋白激酶-活化蛋白-1/c-Fos信号通路减轻急性呼吸窘迫综合征动物模型中的炎症反应并缓解中性粒细胞募集。
Evid Based Complement Alternat Med. 2022 Jun 30;2022:4444513. doi: 10.1155/2022/4444513. eCollection 2022.
3
COVID-19 infection: an overview on cytokine storm and related interventions.COVID-19 感染：细胞因子风暴及相关干预措施概述。
Virol J. 2022 May 26;19(1):92. doi: 10.1186/s12985-022-01814-1.
4
Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism.肌肉衍生白细胞介素-6 的抗炎作用及其在脂代谢中的作用。
Int J Mol Sci. 2021 Sep 13;22(18):9889. doi: 10.3390/ijms22189889.
5
Interleukin-17A (IL-17A): A silent amplifier of COVID-19.白细胞介素-17A（IL-17A）：沉默放大 COVID-19 的“帮凶”。
Biomed Pharmacother. 2021 Oct;142:111980. doi: 10.1016/j.biopha.2021.111980. Epub 2021 Jul 29.
6
Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients.白细胞介素-8 作为 2019 年冠状病毒病患者疾病预后的生物标志物。
Front Immunol. 2021 Jan 8;11:602395. doi: 10.3389/fimmu.2020.602395. eCollection 2020.
本文引用的文献
1
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.探讨治疗 COVID-19 患者肺炎和急性呼吸窘迫综合征相关细胞因子风暴的药理学方法。
Crit Care. 2020 Jun 11;24(1):331. doi: 10.1186/s13054-020-03020-3.
2
SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.严重急性呼吸综合征冠状病毒2型与冠状病毒病2019：白细胞介素-6（IL-6）是急性呼吸窘迫综合征发病的“罪魁祸首”吗？除了托珠单抗还有什么？可溶性糖蛋白130融合蛋白（SGP130Fc）
Cytokine X. 2020 Jun;2(2):100029. doi: 10.1016/j.cytox.2020.100029. Epub 2020 May 14.
3
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎：意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
4
Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling.白细胞介素-6家族信号转导子gp130的不同可溶性形式微调白细胞介素-6反式信号传导的阻断作用。
J Biol Chem. 2016 Jul 29;291(31):16186-96. doi: 10.1074/jbc.M116.718551. Epub 2016 May 23.
5
IL-6 as a keystone cytokine in health and disease.IL-6 作为健康与疾病中的关键细胞因子。
Nat Immunol. 2015 May;16(5):448-57. doi: 10.1038/ni.3153.
6
Interleukin-6 and its receptors: a highly regulated and dynamic system.白细胞介素-6及其受体：一个高度调控且动态的系统。
Cytokine. 2014 Nov;70(1):11-20. doi: 10.1016/j.cyto.2014.05.024. Epub 2014 Jun 28.
7
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.阻断白细胞介素 6/糖蛋白 130 信号转导的治疗策略。
J Clin Invest. 2011 Sep;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1.
8
The pro- and anti-inflammatory properties of the cytokine interleukin-6.细胞因子白细胞介素-6的促炎和抗炎特性。
Biochim Biophys Acta. 2011 May;1813(5):878-88. doi: 10.1016/j.bbamcr.2011.01.034. Epub 2011 Feb 4.
Zotero 插件